Dexamethasone reduces death in hospitalised patients
In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). NDM's Peter Horby, Professor of Emerging Infectious Diseases and one of the Chief Investigators for the trial, said, ‘Dexamethasone is the first drug to be shown to improve survival in COVID-19. This is an extremely welcome result'
See full story here
Posted on: 17/06/2020